Image Alt


PHOENIX gGmbH founded to support innovation in nano-pharmaceutical development

A new company has been founded to provide much-needed support to industry, SMEs, startups and research groups developing nano-pharmaceuticals. PHOENIX OITB gGmbH, founded in November 2023, offers an “all-in-one” Single Entry Point to users, providing manufacturing, characterization, testing and innovation-related consulting services including regulatory and business guidance to accelerate maturity of nano-pharmaceuticals and diagnostic agents.

With a strong vision to remove barriers to nano-pharmaceutical innovation, PHOENIX offers affordable and easy access to a consolidated network of facilities, technologies, services and expertise from across Europe for all the technology transfer aspects, i.e., characterization, in vitro and in vivo testing, validation up to scale-up, regulatory guidance and GMP-compliant manufacturing.

Customers contacting the PHOENIX Single Entry Point (SEP) will meet with a dedicated contact person to evaluate their needs. The customer will then be matched with relevant experts providing the desired services and obtain a comprehensive plan of services. PHOENIX SEP’s portfolio is continuously updated based on customer and market needs. The PHOENIX network covers the entire supply chain from bench to bedside, as well as every administration route (e.g. oral, IV, dermal, etc.).

Available services are categorised within physico-chemical characterisation, in vitro charactertisation, in vivo characterisation, GMP manufacturing and innovation. A full description of comprehensive services will be found on the website soon.


PHOENIX-OITB aims to enable the seamless, timely and cost-friendly transfer of nano-pharmaceuticals from lab bench to clinical trials by providing the necessary advanced, affordable and easily accessible PHOENIX Single-Entry-Point. 

PHOENIX-OITB gGmbH is a non-profit organisation with headquarters based in Germany. Founding members are MyBiotech GmbH (Germany), BioNanoNet Forschungsgesellschaft mbH (Austria), Luxembourg Institute of Science and Technology (Luxembourg), Nanomol Technologies (Spain), and Research Center Pharmaceutical Engineering GmbH (Austria).

PHOENIX SEP can be found under

Follow us on LinkedIn.